Hemophilia B Market Growing at a CAGR of around 7.1%

Hemophilia B Market
The Hemophilia B Market was valued at ~USD 5.4 billion in 2024 and is projected to reach ~USD 10.8 billion by 2034, growing at a CAGR of around 7.1%. Growth is driven by rising diagnosis rates, wider global access to factor IX therapies, and increasing adoption of long-acting recombinant and gene therapy-based treatments.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71654

Key Market Drivers
• Increased adoption of extended half-life recombinant factor IX products.
• Growing demand for prophylactic therapy in children and adults.
• Advancements in gene therapy, offering long-term or near-curative treatment potential.
• Improved screening and newborn diagnostic programs for inherited bleeding disorders.

Challenges
• Very high cost of recombinant and gene therapy products.
• Limited diagnostic and treatment access in low-income regions.
• Risk of inhibitor development in some patients, complicating long-term management.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71654/hemophilia-b-market

Market Segmentation
By Treatment
• Recombinant factor IX (standard & extended half-life)
• Plasma-derived factor IX
• Gene therapy
• Supportive/adjunctive therapies

By Therapy Type
• On-demand treatment
• Prophylaxis (major share, rapidly growing)

By End User
• Hospitals
• Hemophilia treatment centers
• Specialty clinics

By Distribution Channel
• Hospital pharmacies
• Specialty pharmacies
• Online pharmacies

Regional Snapshot
• North America leads due to strong uptake of gene therapy and extended half-life factor IX products.
• Europe maintains significant market share through structured hemophilia care systems and reimbursement support.
• Asia-Pacific is the fastest-growing region as awareness, screening programs, and treatment availability continue to expand.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71654

Key Companies
Pfizer, CSL Behring, Novo Nordisk, Takeda, Sanofi, Catalyst Biosciences, Bayer.

Future Outlook
The market will grow significantly as gene therapy, long-acting FIX products, and next-generation recombinant technologies continue to advance. Expansion of hemophilia treatment centers and improved affordability programs will further strengthen global adoption.

This report is also available in the following languages : Japanese (血友病B市場), Korean (혈우병 B 시장), Chinese (B型血友病市场), French (Marché de l'hémophilie B), German (Hämophilie-B-Markt), and Italian (Mercato dell'emofilia B), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71654

Our More Reports:

Gluten Sensitivity Market
https://exactitudeconsultancy.com/reports/71142/gluten-sensitivity-market

Inguinal Hernia Market
https://exactitudeconsultancy.com/reports/71142/gluten-sensitivity-market

Nonalcoholic Steatohepatitis Market
https://exactitudeconsultancy.com/reports/71159/nonalcoholic-steatohepatitis-market

Overt Hepatic Encephalopathy Market
https://exactitudeconsultancy.com/reports/71156/overt-hepatic-encephalopathy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.